Measurement of anti-pneumococcal capsular polysaccharides (anti-PnPs) IgG titers is an important tool in the immunologic assessment of patients with suspected immunodeficiency disorders (ID) to reduce the morbi-mortality and minimize severe infections. Retrospectively, we studied the relationship among anti-PnPs IgG response to 3 doses of Prevenar®13, levels of immune system components, leukocyte populations, and clinical data in children with ID. Serum samples were collected at least 4 weeks post vaccination. Subsequently, multi-serotype enzyme-linked immunosorbent assay (ELISA) was performed. Eighty-seven children (under 12 years) were enrolled. Primary immunodeficiency disorder (PID) was the most common disorder (45) followed by possible immunodeficiency disorder (POID) (19), secondary immunodeficiency disorder (SID) (15), and mixed immunodeficiency disorder (MID) (8). The median age was 3 (1.50–5.33) years, 65% of patients were male. Deficient production of anti-PnPs IgG (titer ≤ 50 mg/L) was detected in 47 patients (54%), especially in the MID group, all of them under immunosuppressive therapy. In PCV13 responders, the mean of leukocyte population levels was higher with statistically significance differences in CD4 + /CD8 + T lymphocytes (p = 0.372, p = 0.014) and CD56 + /CD16 + NK (p = 0.016). Patients with previous bone marrow transplantation were the worst PCV13 responders. Pneumococcal IgG antibody titers (post-vaccination) along with clinical and analytical markers represented.

抗肺炎球菌荚膜多糖 (anti-PnPs) IgG 滴度的测量是对疑似免疫缺陷病 (ID) 患者进行免疫学评估以降低发病率和最大程度减少严重感染的重要工具。我们回顾性地研究了 ID 儿童对 3 剂 Prevenar®13 的抗 PnPs IgG 反应、免疫系统成分水平、白细胞数量和临床数据之间的关系。疫苗接种后至少 4 周收集血清样品。随后，进行了多血清型酶联免疫吸附试验（ELISA）。登记了 87 名儿童（12 岁以下）。原发性免疫缺陷病 (PID) 是最常见的疾病 (45)，其次是可能的免疫缺陷病 (POID) (19)、继发性免疫缺陷病 (SID) (15)、和混合免疫缺陷病 (MID) (8)。中位年龄为 3 (1.50–5.33) 岁，65% 的患者为男性。47 名患者 (54%) 检测到抗 PnPs IgG 产生不足（滴度≤ 50 mg/L），尤其是在 MID 组，他们都接受了免疫抑制治疗。在 PCV13 应答者中，白细胞群体水平的平均值更高，CD4 + /CD8 + T 淋巴细胞具有统计学显着差异（p = 0.372，p  = 0.014) 和 CD56 + /CD16 + NK ( p  = 0.016)。先前进行过骨髓移植的患者是最差的 PCV13 应答者。肺炎球菌 IgG 抗体滴度（接种疫苗后）以及临床和分析标记物。